Table 1 Demographic and clinical parameters of enrolled patients(n=221)
Parameters | Classification | FFAs | P | |
|---|---|---|---|---|
Low(n=106) | High(n=115) | |||
Age (years) | >60 | 32 (30.19%) | 40 (34.78%) | 0.477 |
≤60 | 74 (69.81%) | 75 (65.22%) | ||
Sex | Male | 65 (61.32%) | 63 (54.78%) | 0.343 |
Female | 41 (38.68%) | 52 (45.22%) | ||
B symptoms | Absent | 88 (83.02%) | 76 (66.09%) | 0.005 |
Present | 18 (16.98%) | 39 (33.91%) | ||
LDH | >ULN | 31 (29.25%) | 71 (61.74%) | <0.001 |
Normal | 75 (70.75%) | 44 (38.26%) | ||
ECOG score | 0-1 | 88 (83.02%) | 83 (72.17%) | 0.076 |
2-4 | 18 (16.98%) | 32 (27.83%) | ||
Ann Arbor Stage | I-II | 44 (41.51%) | 38 (33.04%) | 0.212 |
III-IV | 62 (58.49%) | 77 (66.96%) | ||
Extranodal | > 1 | 23 (21.70%) | 41 (35.65%) | 0.026 |
disease | ≤ 1 | 83 (78.30%) | 74 (64.35%) | |
IPI | Low risk (0-1) | 52 (49.06%) | 36 (31.30%) | 0.008 |
Low-intermediate risk (2) | 28 (26.42%) | 26 (22.61%) | ||
High-intermediate risk (3) | 16 (15.09%) | 34 (29.57%) | ||
High risk (4-5) | 10 (9.43%) | 19 (16.52%) | ||
Cell of origin | GCB | 36 (33.96%) | 40 (34.78%) | 0.416 |
non-GCB | 56 (52.83%) | 66 (57.39%) | ||
Undetermined | 14 (13.21%) | 9 (7.83%) | ||